Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Warrant (NQ:NAMSW)

18.80 +0.81 (+4.50%)
Streaming Delayed Price Updated: 12:34 PM EDT, Jun 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Warrant

< Previous 1 2 3 4 Next >
News headline image
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
NewAmsterdam to review data on webcast conference call on June 5, 2023 at 8:00 a.m. ET 
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
News headline image
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.